SecBot SecBot
Biotech Drug Report Generated Nov 5, 2026

SPY130

SYRE·Spyre Therapeutics, Inc.
NEUTRAL
Drug Impact Rating6/10
Trial phase
Phase 2
Time to market
SPY130 is in Phase 2 testing with combination data expected in Q3 2027. If successful, Phase 3 trials would follow, meaning potential approval is likely several years away, likely 2029 or later.
Why 6/10
The next hard catalyst for SPY130 is the SKYLINE Part B Phase 2 combination topline data, expected in Q3 2027 (roughly 8-10 months from today). This is a mid-stage readout on a major pipeline asset at a company with multiple programs, warranting a score of 6.
Actionable Insight NEUTRAL

The next major catalyst for SPY130 is the SKYLINE Part B combination data expected in Q3 2027. Positive results would validate the combination strategy and could accelerate the program toward Phase 3. Negative or mixed data would raise questions about the additive benefit of combining anti-alpha4beta7 and anti-IL-23 antibodies. Interim updates or enrollment completion announcements could move the stock in the interim.

Price Chart

Loading chart...

Executive Summary

SPY130 is a preclinical-to-Phase 2 combination therapy from Spyre Therapeutics (NASDAQ: SYRE), pairing two long-acting antibodies (anti-alpha4beta7 and anti-IL-23) for inflammatory bowel disease. All three monotherapy components (SPY001, SPY002, SPY003) hit their primary endpoints in Part A of the Phase 2 SKYLINE trial in 2026, clearing the path for the combination study. SPY130 is now being tested in Part B of SKYLINE, which is enrolling faster than expected with topline combination data anticipated in Q3 2027. Spyre has a strong cash position of $1.47B and broad institutional support, but the drug is still in mid-stage development with no near-term binary catalyst and the company faces significant cash burn and recent dilutive financing.

How It Works

SPY130 is a combination of two engineered antibodies given together as a single treatment. SPY001 blocks alpha4beta7, a protein on immune cells that helps them travel to the gut and cause inflammation. SPY003 blocks IL-23, a signaling protein that drives inflammatory responses. By hitting both targets at once, SPY130 aims to more completely control inflammation in inflammatory bowel disease (ulcerative colitis and Crohn's disease) than either antibody alone. The antibodies are engineered for a long half-life, meaning patients could receive them as a shot under the skin every 3 to 6 months instead of the frequent infusions required by current therapies.

Trial Status

SPY130 is being evaluated in Part B of the Phase 2 SKYLINE-UC trial (NCT07012395), a platform study in moderate-to-severe ulcerative colitis. The combination portion is enrolling faster than expected with an increased enrollment target. All three monotherapy components (SPY001, SPY002, SPY003) previously met their primary endpoints in Part A of the same trial. Topline combination data is expected in Q3 2027.

The Two-Sided Case

▲ Bull Case6
All three monotherapy components of SPY130 (SPY001, SPY002, SPY003) met their primary endpoints in Part A of the Phase 2 SKYLINE trial, providing a strong foundation for the combination study.
The SKYLINE Part B combination portion is enrolling faster than expected, enabling an increased enrollment target, suggesting strong investigator and patient interest.
SPY130 targets two validated IBD mechanisms (alpha4beta7 integrin and IL-23) with extended-half-life antibodies designed for quarterly or twice-annual subcutaneous dosing, potentially offering best-in-class convenience.
Spyre has a robust cash position of $1.47B pro forma (post-Q3 2026 and the October offering), funding operations into H2 2029 and removing near-term financing risk.
Analyst consensus is strongly bullish: 21 buy/strong buy ratings vs 2 hold, with a mean price target of $122.53 (23.4% upside from $99.27).
Major institutional holders including Fidelity ($1.16B), BlackRock ($578M), and RTW Investments ($377M) added or doubled positions in Q2 2026.
▼ Bear Case5
SPY130 is still in Phase 2 with no topline combination data expected until Q3 2027, leaving a long wait with binary risk. The combination approach is unproven in the clinic; preclinical additive efficacy may not translate to humans.
Spyre reported a Q3 2026 net loss of $96.1M, widening sharply from $11.2M a year earlier, with operating cash burn of $77.5M in the quarter alone, raising questions about long-term capital efficiency.
The company completed a dilutive $350M public offering in October 2026 at $85/share, increasing share count by ~4.1M shares (roughly 5% dilution) and pressuring the stock.
SPY072, another pipeline asset, failed primary endpoints in PsA and axSpA and was discontinued in rheumatic disease, highlighting clinical execution risk across the pipeline.
All pipeline candidates are pre-revenue; the company has no approved products and depends entirely on clinical success.

Upcoming Catalysts

  • SKYLINE Part B combination topline data (including SPY130, SPY120, SPY230) expected Q3 2027
  • Potential preclinical or translational data presentations at medical conferences (e.g., ECCO, DDW, UEGW)
  • Enrollment completion updates for the SKYLINE Part B trial

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Spyre Therapeutics, Inc. PRESS-RELEASE SYRE ·Originating report

Sources · 9

Hover a chip for the title
1 spyre.com2 clinicaltrials.gov3 ir.spyre.com4 markets.businessinsider.com5 markets.businessinsider.com6 sec.gov7 synapse.patsnap.com8 adisinsight.springer.com9 insidermonkey.com